阿立哌唑（OPC-14597）是一种非典型抗精神病药，作为多巴胺D2受体的部分激动剂和5-HT2A/2B受体的反向激动剂，对5-HT1A、5-HT2C、D3和D4受体具有部分激动活性，可用于精神分裂症和COVID-19的研究。
|
英文别名 (English Synonym) |
Aripiprazole |
|
中文名称 (Chinese Name) |
阿立哌唑 |
|
靶点 (Target) |
Dopamine Receptor |
|
通路 (Pathway) |
Neuroscience |
|
CAS号 (CAS NO.) |
129722-12-9 |
|
分子式 (Formula) |
C23H27Cl2N3O2 |
|
分子量 (Molecular Weight) |
448.39 |
|
纯度 (Purity) |
≥98% |
|
溶解性 (Solubility) |
溶于DMSO |
-25~-15℃保存，有效期3年
[1] Crespo-Facorro B, Ruiz-Veguilla M, Vázquez-Bourgon J, Sánchez-Hidalgo AC, Garrido-Torres N, Cisneros JM, Prieto C, Sainz J. Aripiprazole as a Candidate Treatment of COVID-19 Identified Through Genomic Analysis. Front Pharmacol. 2021 Mar 2;12:646701. doi: 10.3389/fphar.2021.646701. PMID: 33762960; PMCID: PMC7982825.[2]Russo E, Citraro R, Davoli A, Gallelli L, Di Paola ED, De Sarro G. Ameliorating effects of aripiprazole on cognitive functions and depressive-like behavior in a genetic rat model of absence epilepsy and mild-depression comorbidity. Neuropharmacology. 2013 Jan;64:371-9. doi: 10.1016/j.neuropharm.2012.06.039. Epub 2012 Jul 2. PMID: 22766393.
